View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2011	Dec. 13, 2011
Entity Information [Line Items]
Entity Registrant Name	NEWLINK GENETICS CORPORATION
Entity Central Index Key	0001126234
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2011
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		20,591,183

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2011	Dec. 31, 2010
Assets
Cash and cash equivalents	$ 6,287	$ 10,572
Certificates of deposit	0	2,269
Prepaid expenses	1,997	959
State research and development credit receivable	140	230
Interest receivable	0	8
Other receivables	458	604
Total current assets	8,882	14,642
Leasehold improvements and equipment:
Leasehold improvements	3,804	3,804
Computer equipment	704	691
Lab equipment	3,327	3,165
Total leasehold improvements and equipment	7,835	7,660
Less accumulated depreciation and amortization	(2,743)	(2,224)
Leasehold improvements and equipment, net	5,092	5,436
Total assets	13,974	20,078
Liabilities and Equity
Accounts payable	256	552
Accrued expenses	1,693	1,554
Deferred rent	922	951
Notes payable to Iowa Department of Economic Development	6,000	0
Obligations under capital leases	130	116
Current portion of long term debt	93	91
Deposits on restricted shares	0	1
Total current liabilities	9,094	3,265
Long term liabilities:
Obligations under capital leases	117	145
Total long-term liabilities	988	7,087
Total liabilities	10,082	10,352
Redeemable preferred stock, $0.01 par value: Authorized shares — 14,327,777 at September 30, 2011, and December 31, 2010; issued and outstanding shares — 13,850,113 at September 30, 2011, and 13,417,435 at December 31, 2010; liquidation preference — $75,303 at September 30, 2011, and $61,782 at December 31, 2010	75,274	61,745
Equity (deficit):
Common stock, $0.01 par value: Authorized shares — 38,833,334 at September 30, 2011, and December 31, 2010; issued and outstanding shares — 3,678,615 at September 30, 2011, and 3,628,082 at December 31, 2010	37	36
Additional paid-in capital	3,217	7,374
Notes receivable for common stock	0	(13)
Deficit accumulated during the development stage	(75,666)	(63,389)
Total NewLink Genetics stockholders’ deficit	(71,382)	(54,962)
Equity attributable to noncontrolling interests	0	2,943
Total deficit	(71,382)	(52,019)
Commitments
Total liabilities and equity	13,974	20,078
Blank Check Preferred Stock [Member]
Equity (deficit):
Preferred stock	0	0
Preferred Stock Series A [Member]
Equity (deficit):
Preferred stock	1,030	1,030
Iowa Department of Economic Development [Member]
Long term liabilities:
Notes payable	0	6,000
Iowa State University Research Park [Member]
Long term liabilities:
Notes payable	571	642
City of Ames [Member]
Long term liabilities:
Notes payable	$ 300	$ 300

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2011	Dec. 31, 2010
Stockholders' Equity:
Redeemable preferred stock, par value	$ 0.01	$ 0.01
Redeemable preferred stock, authorized shares	14,327,777	14,327,777
Redeemable preferred stock, issued shares	13,850,113	13,417,435
Redeemable preferred stock, shares outstanding	13,850,113	13,417,435
Redeemable preferred stock, liquidation preference	$ 75,303	$ 61,782
Common stock, par value	$ 0.01	$ 0.01
Common stock, authorized shares	38,833,334	38,833,334
Common stock, issued shares	3,678,615	3,628,082
Common stock, outstanding shares	3,678,615	3,628,082
Blank Check Preferred Stock [Member]
Stockholders' Equity:
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized shares	1,388,889	1,388,889
Preferred stock, issued shares	0	0
Preferred stock, shares outstanding	0	0
Preferred Stock Series A [Member]
Stockholders' Equity:
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized shares	450,000	450,000
Preferred stock, issued shares	420,000	420,000
Preferred stock, shares outstanding	420,000	420,000
Preferred stock, liquidation preference	$ 1,050	$ 1,050

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		148 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011
Grant revenue	$ 430	$ 375	$ 1,571	$ 1,105	$ 5,416
Operating expenses:
Research and development	3,301	3,948	10,276	9,644	56,339
General and administrative	1,101	1,539	3,553	3,823	27,709
Total operating expenses	4,402	5,487	13,829	13,467	84,048
Loss from operations	(3,972)	(5,112)	(12,258)	(12,362)	(78,632)
Other income and expense:
Miscellaneous income	0	62	1	70	354
Forgiveness of debt	0	0	0	0	449
Interest income	2	(1)	10	22	1,752
Interest expense	(16)	(15)	(31)	(34)	(132)
Other income (expense), net	(14)	46	(20)	58	2,423
Net loss	(3,986)	(5,066)	(12,278)	(12,304)	(76,209)
Less net loss attributable to noncontrolling interest	0	35	1	186	583
Net loss attributable to NewLink	$ (3,986)	$ (5,031)	$ (12,277)	$ (12,118)	$ (75,626)
Net loss per common share, basic and diluted	$ (1.09)	$ (1.49)	$ (3.37)	$ (3.72)
Weighted-average common shares outstanding, basic	3,658,122	3,371,924	3,647,127	3,254,771
Weighted-average common shares outstanding, diluted	3,658,122	3,371,924	3,647,127	3,254,771

Consolidated Statement of Equity (Deficit) - 9 months ended Sep. 30, 2011 - USD ($) $ in Thousands	Total	Preferred Stock Series A [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Notes Receivable For Common Stock [Member]	Deficit Accumulated During the Development Stage [Member]	Total Newlink Genetics Stockholders' Equity [Member]	Non-Controlling Interest [Member]
Balance at Dec. 31, 2010	$ (52,019)	$ 1,030	$ 36	$ 7,374	$ (13)	$ (63,389)	$ (54,962)	$ 2,943
Balance (shares) at Dec. 31, 2010	3,628,082		3,628,082
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock compensation	$ 1,410		$ 0	1,410			1,410
Stock compensation (shares)			11,905
Exercise of stock options	18			18			18
Exercise of stock options (shares)			9,263
Receipt of payment on note receivable	13				13		13
Conversion of preferred stock to common stock	115			115			115
Conversion of preferred stock to common stock (shares)			8,505
Issuance of dividend paid in common stock			$ 1	(1)
Issuance of dividend paid in common stock (shares)			20,860
Accretion of redemption feature of preferred stock	(7)			(7)			(7)
Acquisition of noncontrolling interest	(8,634)			(5,692)			(5,692)	(2,942)
Net loss	(12,278)					(12,277)	(12,277)	(1)
Balance at Sep. 30, 2011	$ (71,382)	$ 1,030	$ 37	$ 3,217	$ 0	$ (75,666)	$ (71,382)	$ 0
Balance (shares) at Sep. 30, 2011	3,678,615		3,678,615

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended		148 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011
Cash Flows From Development Activities
Net loss	$ (12,278)	$ (12,304)	$ (76,209)
Adjustments to reconcile net loss to net cash used in development activities:
Share-based compensation	1,410	1,158	4,214
Depreciation and amortization	520	422	2,794
In-process research and development expenses - OncoRx	0	819	1,428
In-process research and development expenses —Reconstitute	0	201	201
Forgiveness of debt	0	0	(449)
Forgiveness of notes receivable from related parties	0	0	350
Changes in operating assets and liabilities:
Prepaid expenses	(958)	667	(1,917)
State research and development credit receivable	90	(55)	(140)
Interest due on notes receivable	8	62	0
Other receivables	65	0	(539)
Accounts payable	(297)	(700)	(494)
Accrued expenses and deferred rent	110	342	2,615
Net Cash Used in Development Activities	(11,330)	(9,388)	(68,146)
Cash Flows From Investing Activities
Purchase of investments	0	0	(8,800)
Sale of investments	2,269	0	8,800
Notes receivable from related parties	0	850	(350)
Purchase of equipment	(94)	(2,893)	(6,582)
Cash paid for OncoRx	0	0	(120)
Net cash provided by (used in) investing activities	2,175	(2,043)	(7,052)
Cash Flows From Financing Activities
Cash received from noncontrolling interest investment	0	912	3,479
Issuance of common stock	0	0	192
Issuance of common stock from exercise of stock options	18	32	158
Issuance of common stock from exercise of warrants	0	0	3,113
Repurchase of common stock	0	0	(501)
Repayments (advances) of notes receivable for common stock	13	25	0
Proceeds from subsidiary common stock option exercise	0	64	141
Proceeds from preferred stock	5,000	0	67,743
Proceeds from notes payable	0	1,100	7,759
Principal payments on debt	(69)	(45)	(346)
Payments under capital lease obligations	(92)	(65)	(253)
Net cash provided by financing activities	4,870	2,023	81,485
Net (decrease) increase in cash and cash equivalents	(4,285)	(9,408)	6,287
Cash and cash equivalents at Beginning of Period	10,572	15,217
Cash and cash equivalents at End of Period	6,287	5,809	6,287
Supplemental disclosure of cash flows information:
Cash paid for interest	31	34	93
Noncash financing and investing activities:
Accretion on redeemable preferred stock	7	0	112
Purchased leasehold improvements and equipment in accounts payable	24	0	793
Common stock issued to shareholders of OncoRx as part of acquisition	0	932	1,654
Issuance of common stock dividend to Series AA preferred shareholders	0	1	5
Assets acquired under capital lease	$ 80	$ 0	$ 542

Description of Business and Development Stage Activities	9 Months Ended
	Sep. 30, 2011
Development Stage Enterprises [Abstract]
Development Stage Enterprise General Disclosures [Text Block]	Description of Business and Development Stage Activities On June 4, 1999, NewLink Genetics Corporation (“NewLink”) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for cancer and other diseases. NewLink initiated operations in April of 2000, which primarily consist of research and development. In 2005, NewLink created a wholly owned subsidiary, BioProtection Systems Corporation (“BPS”). NewLink contributed certain licensing agreements and other intangible assets for BPS to create vaccines against potential biological terror threats. NewLink and BPS (together referred to herein as the “Company,” “we,” “us,” or “our”) are development stage enterprises and are devoting substantially all of their efforts toward research and development. On October 19, 2011, the Company’s board of directors approved a 2.1-for-one reverse split of the Company’s common stock to be effected prior to the effective date of the Company’s registration statement. In connection with the reverse split, the Company filed a Certificate of Amendment of the Restated Certificate of Incorporation with the Secretary of State of Delaware on October 25, 2011 making the reverse split effective. All share and per share amounts have been retroactively restated in the accompanying financial statements and notes for all periods presented. The Company has never earned revenue from sales of its drugs under development. The Company has, from June 4, 1999 (inception) through September 30, 2011 generated a cumulative deficit of $75.7 million. The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company received $37.5 million as a result of the recent initial public offering (“IPO”), which is expected to fund operations through 2013. The generation of additional financing may be necessary for the Company to continue operations in the future. There can be no assurance, however, that such financing will be available on terms acceptable to the Company or at all.

- Definition

The entire disclosure for all or part of the detailed information required for development stage enterprises. The information may also be disclosed on an element-by-element basis. Information may include an identification of the current or prior year financial statements of the entity, its development stage subsidiaries, or its investees as those of one or more development stage enterprises; a description of the nature of the development stage activities in which each enterprise is engaged; and in the first fiscal year in which each enterprise is no longer considered a development stage enterprise, a statement that in prior years the enterprise had been in the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 7
-Paragraph 11, 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 225
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472436&loc=d3e38614-110930

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 210
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472471&loc=d3e38015-110924

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 215
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38313-110927

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 215
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472370&loc=d3e38297-110927

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38942-110933

+ Details

Initial Public Offering	9 Months Ended
Initial Public Offering	Sep. 30, 2011
Initial Public Offering [Abstract]
Initial Public Offering [Text Block]	Initial Public Offering On November 10, 2011, the Company’s Registration Statement on Form S-1 was declared effective for its IPO, pursuant to which the Company sold 6,200,000 shares of its common stock at a public offering price of $7.00 per share. Proceeds, net of underwriting discounts, commissions and other transaction costs were approximately $37.5 million. Upon the closing of the IPO, all of the outstanding shares of the Company’s preferred stock were converted to shares of the Company’s common stock and reclassified from a liability to equity. Prepaid expenses as of September 30, 2011 included $1.9 million of deferred costs for legal, accounting and other direct costs related to the IPO. These costs will be reclassified to additional paid-in capital as a reduction of the IPO proceeds.

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Basis of Presentation The interim financial statements have been prepared and presented by the Company in accordance with accounting principles generally accepted in the United States (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”), without audit, and reflect all adjustments necessary to present fairly the Company’s interim financial information. The accounting principles and methods of computation adopted in these financial statements are the same as those of the audited financial statements for the year ended December 31, 2010. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. The accompanying unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2010, included in the Company’s Registration Statement on Form S-1 (as amended). The financial results for any interim period are not necessarily indicative of financial results for the full year. In addition to those accounting policies set forth below, the accounting policies we follow are set forth in “Financial Statements and Supplementary Data, note 2 — Significant Accounting Policies” to our financial statements included in the Company’s Registration Statement on Form S-1 (as amended) filed with the SEC on November 10, 2011.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Name Statement of Position (SOP)
-Publisher AICPA
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Name FASB Interpretation (FIN)
-Publisher FASB
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Significant Accounting Policies

9 Months Ended

Sep. 30, 2011

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Significant Accounting Policies


(a)	Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.


(b)	Principles of Consolidation

The consolidated financial statements include the financial statements of NewLink and BPS. All significant intercompany balances and transactions have been eliminated in consolidation.


(c)	Financial Instruments and Concentrations of Credit Risk

The fair values of cash and cash equivalents, certificates of deposit, prepaid expenses, receivables, accounts payable, and accrued liabilities, which are recorded at cost, approximate fair value based on the short-term nature of these financial instruments. Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and certificates of deposit. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality securities such as money market funds. The fair value of notes payable and capital lease obligations was $7.2 million and $7.3 million as of September 30, 2011 and December 31, 2010, respectively.


(d)	Unaudited Interim Financial Data

The accompanying balance sheet as of September 30, 2011, statements of operations and of cash flows for the nine months ended September 30, 2011 and 2010 and for the period from June 4, 1999 (inception) through September 30, 2011 and the statements of equity (deficit) for the nine months ended September 30, 2011 are unaudited. The financial data and other information disclosed in these notes to the financial statements related to the nine-month periods ended September 30, 2011 and 2010 and for the period from June 4, 1999 (inception) through September 30, 2011 are unaudited.

Immaterial Corrections

9 Months Ended

Sep. 30, 2011

Accounting Changes and Error Corrections [Abstract]

Accounting Changes and Error Corrections [Text Block]

Immaterial Corrections

The Company has corrected immaterial errors in the historical financial statements related to the stock compensation and research and development expenses. The errors related to the fair value and volatility assumptions used in the stock compensation calculations, the allocation of these expenses to research and development activities, adjusting certain research and development expenses, and the correction of other classification errors within research and development expenses and general and administrative expenses. In accordance with the SEC’s Staff Accounting Bulletin (SAB) No. 99, Materiality, and SAB No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, management evaluated the materiality of the errors from qualitative and quantitative perspectives and concluded that the errors were immaterial to the Company’s historical financial statements. Consequently, the Company has revised its historical financial statements for the nine months ended September 30, 2010 as noted in the table below. The Company has also revised the disclosure of the inputs to the Black-Scholes model for estimating the fair value of stock options to disclose the assumptions now used in the calculation.



	As previously reported			Adjustments			As adjusted
Nine months ending September 30, 2010
Research and development	$	6,921		$	2,723		$	9,644
General and administrative	5,610			(1,787		)	3,823
Net loss	(11,181		)	937			(12,118		)
Net loss per common share	(3.44		)				(3.72		)

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References + Details

Preferred Stock

9 Months Ended

Sep. 30, 2011

Preferred Stock [Abstract]

Preferred Stock [Text Block]

Preferred Stock

NewLink’s Restated Certificate of Incorporation, as amended, authorizes the issuance of 17,166,666 shares of preferred stock, $0.01 par value. The NewLink Board of Directors has the authority to issue the preferred stock in one or more series and to fix the voting power and such designations, preferences, and rights subject to approval of outstanding preferred series shareholders. The following is a summary of all preferred stock issued by NewLink and outstanding at September 30, 2011:



	as of September 30, 2011 (in thousands, except share and per share data)
	Issue Price per Share		Shares Authorized	Issued and Outstanding Shares	Liquidation Preference		Carrying Value
Series A	$	2.50	450,000	420,000	$	1,050	$	1,030
Series AA	1.80		1,250,000	1,217,175	2,191		2,191
Series AAA	2.25		377,777	377,410	849		849
Series B	2.50		3,200,000	2,191,193	5,478		5,478
Series BB	4.25		2,000,000	1,883,337	8,004		8,004
Series C	5.00		6,000,000	6,000,000	30,000		30,000
Series D	5.00		1,500,000	1,500,000	7,500		7,500
Series E	31.25		1,000,000	680,998	21,281		21,252
Blank Check Preferred	—		1,388,889	—	—		—
Total				14,270,113	$	76,353	$	76,304

On June 20, 2011, the Company issued and sold to an investor 160,000 shares of Series E preferred stock at a purchase price of $31.25 per share, for aggregate consideration of $5.0 million.

In connection with the completion of the Company’s IPO on November 10, 2011, all of the Company’s shares of preferred stock outstanding at the time of the offering were converted into 14,389,457 shares of common stock. As of November 10, 2011, no liquidation preference remained.

Common Stock Equity Incentive Plan

9 Months Ended

Sep. 30, 2011

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Common Stock Equity Incentive Plan

Share-based employee compensation expense for the nine months ended September 30, 2011 and 2010 and since inception was $1,410,000, $1,158,000 and $3.9 million, respectively, and is allocated between research and development and general and administrative expenses within the consolidated statements of operations. As of September 30, 2011, the total compensation cost related to non-vested option awards not yet recognized was $2.9 million and the weighted average period over which it is expected to be recognized was 1.5 years.

The following table summarizes the stock option activity for the nine months ended September 30, 2011:



	Number of options		Weighted average exercise price		Weighted average remaining contractual term (years)
Outstanding at beginning of period	2,932,772		$	2.67
Options granted	185,037		7.35
Options exercised	(21,072	)	6.52
Options forfeited	(8,653	)	3.52
Options expired	—		—
Outstanding at end of period	3,088,084		$	20.06	7.5
Options exercisable at end of period	2,054,785		$	2.55	7.2

On January 7, 2011, all options to purchase BPS common stock were exchanged for 50,513 options to purchase NewLink stock with a weighted average exercise price of $1.30, which are included in options granted above. See note 10.

As of September 30, 2011, there were an additional 747,932 shares reserved for future issuance under our employee benefit plans, of which 494,047 shares are issuable upon the exercise of options that were granted effective November 10, 2011, upon pricing of the IPO.

The following table summarizes the assumptions used to estimate the fair value of those stock options granted during the nine months ended September 30, 2011 using a Black-Scholes valuation model:



Risk-free interest rate	2.1% - 3.1%
Expected dividend yield	—
Expected volatility	64.5% - 67.7%
Expected term (in years)	5.4 - 7.5
Weighted average grant-date fair value per share	$6.95

The intrinsic value of options exercised during the nine months ending September 30, 2011 was $193,000. The fair value of awards vested during the nine months ending September 30, 2011 was $5.9 million.

During the nine months ended September 30, 2011 and since inception 129,048 and 439,048 stock options and awards were granted to nonemployees, respectively. As a result of the issuance of these options and awards, $294,000 and $703,000 of expense was recorded in the nine months ended September 30, 2011 and since inception, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

+ Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2011
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes The Company incurred no income tax expense for the nine months ended September 30, 2011 and 2010 or since inception. Income tax expense differs from the amount that would be expected after applying the statutory U.S. federal income tax rate primarily due to changes in the valuation allowance for deferred taxes. The valuation allowance for deferred tax assets as of September 30, 2011 and December 31, 2010 was $17.6 million and $15.0 million, respectively. The net change in the total valuation allowance for the nine months ended September 30, 2011 and 2010 was an increase of $2.6 million and $2.4 million, respectively. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected taxable income, and tax planning strategies in making this assessment. Valuation allowances have been established for the entire amount of the net deferred tax assets as of September 30, 2011 and December 31, 2010, due to the uncertainty of future recoverability.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Net Loss per Common Share

9 Months Ended

Sep. 30, 2011

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common share equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, preferred stock, stock options and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

The following table presents the computation of basic and diluted net loss per common share (in thousands, except per share data):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2011			2010			2011			2010
Historical net loss per share
Numerator
Net loss attributable to common stockholders	$	(3,986	)	$	(5,031	)	$	(12,277	)	$	(12,118	)
Denominator
Weighted-average common shares outstanding	3,658			3,372			3,647			3,255
Denominator for basic and diluted net loss per share	3,658			3,372			3,647			3,255
Basic and diluted net loss per common share	$	(1.09	)	$	(1.49	)	$	(3.37	)	$	(3.72	)

The numerator was not adjusted for the stock dividend paid on the Company’s Series AA preferred stock as the impact is not material. Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common equivalent shares):



	As of September 30,
	2011	2010
Preferred stock (1)	10,710,848	7,150,222
Common stock warrants	—	178,571
Common stock options	3,088,084	3,037,664
	13,798,932	10,366,457

_________________________________

(1) Amounts for the Company’s Series BB, C, D and E conversions are computed based on the IPO price of $7.00 per share.

Acquisition of BioProtection Systems Corporation	9 Months Ended
Acquisition of BioProtection Systems Corporation	Sep. 30, 2011
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Acquisition of BioProtection Systems Corporation On January 7, 2011, NewLink acquired all of the minority interest in BPS, by merging a newly-formed subsidiary of NewLink’s with BPS, with BPS as the surviving corporation. In connection with this transaction, NewLink agreed to issue up to an aggregate of 276,304 shares of NewLink’s Series E preferred stock with a value of $8.6 million to the former holders of BPS Series B common stock, Series A preferred stock and Series B preferred stock (other than NewLink). As a result of this transaction, BPS became a wholly-owned subsidiary of NewLink. All options to purchase shares of BPS common stock became options to purchase NewLink’s common stock. The exchange of options was accounted for as a modification of an equity-classified award. The Series E preferred stock was issued with similar price and terms as the shares sold to third-parties in December 2010. As NewLink and BPS are under common control, the acquisition is treated as an equity transaction. The net assets of BPS had a book value of $2.9 million. The remaining amount paid of $5.7 million was recorded as a reduction of additional paid-in capital. No gain or loss was recorded as a result of this transaction.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Appendix F
-Paragraph F4
-Subparagraph e

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1490-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7008-128479

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6996-128479

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1524-128463

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1392-128463

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7000-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1497-128463

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1486-128463

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1383-128463

+ Details

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2011
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Events On November 14, 2011, the Company entered into a Memorandum of Agreement (the “Memorandum”) with Iowa State University Research Park Corporation (“ISURP”). The Memorandum is an addendum to the lease (the “Lease”) dated September 30, 2009 between the Company and ISURP covering the Company’s facilities in Ames, Iowa. The Memorandum adds approximately 26,000 square feet of additional space to the Lease. Under the terms of the Memorandum, (i) the Company’s annual operating rents will increase by approximately $266,000, (ii) ISURP will provide the Company with an improvement allowance of approximately $620,000 and (iii) ISURP will assist the Company to secure approximately $450,000 in debt financing through sources supported by the State of Iowa. In conjunction with the availability of the additional space under the Memorandum, the Company plans to reduce the space historically being leased on a month-to-month basis by approximately 8,900 square feet. On November 14, 2011, the Company entered into a Standard Design-Build Agreement (the “Design-Build Agreement”) with Story Construction Co. (“Story Construction”). Under the Design-Build Agreement, Story Construction will provide construction services to finish approximately 14,000 square feet of the additional space adjoining the Company’s existing facilities in Ames, Iowa. The estimated cost of these improvements is $1.3 million.